true
Icon to close the modal
Support
Turkey
Phone Icon
+90 216 680 10 02
Fax Icon
+90 216 680 16 55
CC_Turkey@bd.com
Modal Close Icon
Icon to close thank you modal
Thank you for contacting our sales team!
A sales representive will get in touch with you shortly.
Middle East & North Africa
Phone Icon
+971 4 5592555
Fax Icon
+971 4 5592599
info_uae@bd.com
Saudi Arabia
Phone Icon
+966 11 472 7933
Fax Icon
+966 11 472 3387
Saudi_info@bd.com
Egypt
Becton Dickinson BV, Scientific Office Mivida Business Park, Building A2, 1st Floor, Office 107, New Cairo, Cairo, Egypt.

LifeStent™ and LifeStent™ XL Vascular Stent System

Contact Us
life_stent_img
Loading
Overview

Proven performance. The LifeStent™ Vascular Stent is FDA-approved stent for the SFA and full popliteal artery. 

Long term sustained effectiveness up to three years, and treatment superiority over balloon angioplasty. 

Engineered for bending, compression, and torsion with dynamic vessel conformability. 

Available in 6 mm and 7 mm diameters; and 150 mm to 170 mm in length.

Additionally, the LifeStent™ Solo™ Vascular Stent is available in 6 mm and 7 mm diameters and 200 mm in length.

true
Features and Benefits
FDA-approved for the SFA and full popliteal artery
Longest lesion length indication (up to 240 mm)1
Unique helical design
Engineered for bending, compression, torsion
Dynamic vessel conformability
Improved lesion coverage with a single stent
EIFUs
Resources

References

1. As of December 2020

2. Laird et al. Nitinol Stent Implantation vs. Balloon Angioplasty for Lesions in the Superficial Femoral and Proximal Popliteal Arteries of Patients With Claudication: Three-Year Follow-up From the RESILIENT Randomized Trial. J Endovasc Ther. 2012;19:1-9. The LifeStent® 5 mm diameter was not included in this trial.

3. RESILIENT I Trial, RESILIENT II Trial, E-TAGIUSS Trial, Retrospective Analysis of LifeStent® Vascular Stent Systems in the Treatment of Long-Segment Lesions, LifeStent® Vascular Stent Delivery System Study (LifeStent® 200 mm Trial),REALITY I Trial,REALITY II Trial, ETAP Trial, CONTINUUM Trial, and RELIABLE Trial. Additional trials ongoing.

Please consult Instructions for Use for product indications for use, contraindications, warnings, precautions, complications, adverse events and detailed safety information.

true

BD-23530

true